应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
AZN 阿斯利康
交易中 05-28 14:50:52 EDT
185.72
+0.07
+0.04%
最高
185.85
最低
183.36
成交量
121.02万
今开
183.78
昨收
185.65
日振幅
1.34%
总市值
2,880亿
流通市值
2,867亿
总股本
15.51亿
成交额
2.24亿
换手率
0.08%
流通股本
15.44亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
阿斯利康将在ASCO 2026公布多项III期数据，涵盖肝癌、乳腺癌、膀胱癌及罕见病疗法
环球市场播报 · 05-22
阿斯利康将在ASCO 2026公布多项III期数据，涵盖肝癌、乳腺癌、膀胱癌及罕见病疗法
欧洲药品管理局对阿斯利康乳腺癌新药给予积极指导意见
环球市场播报 · 05-22
欧洲药品管理局对阿斯利康乳腺癌新药给予积极指导意见
广药接手达安基因；阿斯利康高血压创新药获美国FDA批准
21世纪经济报道 · 05-19
广药接手达安基因；阿斯利康高血压创新药获美国FDA批准
阿斯利康(AZN)旗下创新降压药Baxfendy获批 加码高血压治疗领域
金吾财讯 · 05-18
阿斯利康(AZN)旗下创新降压药Baxfendy获批 加码高血压治疗领域
流行病诊疗板块多股扬升 雅培(ABT)涨1.60%、强生(JNJ)涨1.12%
金吾财讯 · 05-12
流行病诊疗板块多股扬升 雅培(ABT)涨1.60%、强生(JNJ)涨1.12%
世界狼疮日｜“主场时刻”患者关爱行动在沪启幕，助百万"蝶友"迈向临床缓解新篇章
美通社 · 05-10
世界狼疮日｜“主场时刻”患者关爱行动在沪启幕，助百万"蝶友"迈向临床缓解新篇章
多家药企高管生变：恒瑞、复星、阿斯利康、辉瑞…
赛柏蓝 · 05-07
多家药企高管生变：恒瑞、复星、阿斯利康、辉瑞…
跨国药企业绩大爆发，集体加仓中国
21世纪经济报道 · 05-07
跨国药企业绩大爆发，集体加仓中国
诚益生物冲刺港股：年亏损4460万美元 业务深度绑定阿斯利康
雷递网 · 05-03
诚益生物冲刺港股：年亏损4460万美元 业务深度绑定阿斯利康
伯恩斯坦将阿斯利康目标价从20500便士下调至18600便士。
智通财经 · 05-01
伯恩斯坦将阿斯利康目标价从20500便士下调至18600便士。
阿斯利康乳腺癌候选药物未获FDA咨询委员会投票通过
环球市场播报 · 05-01
阿斯利康乳腺癌候选药物未获FDA咨询委员会投票通过
FDA顾问委员会推荐阿斯利康Truqap用于PTEN缺陷型转移性激素敏感性前列腺癌
美股速递 · 05-01
FDA顾问委员会推荐阿斯利康Truqap用于PTEN缺陷型转移性激素敏感性前列腺癌
阿斯利康行使选择权 根据协议条款向Pintree Therapeutics支付2500万美元交割款项
美股速递 · 04-30
阿斯利康行使选择权 根据协议条款向Pintree Therapeutics支付2500万美元交割款项
阿斯利康宣布3亿英镑对英投资，涵盖去年暂停的剑桥研发基地后续建设
美股速递 · 04-29
阿斯利康宣布3亿英镑对英投资，涵盖去年暂停的剑桥研发基地后续建设
阿斯利康CEO：英美医药协议将惠及患者，提升药物可及性
美股速递 · 04-29
阿斯利康CEO：英美医药协议将惠及患者，提升药物可及性
阿斯利康(AZN.US)哮喘三联疗法获批上市
智通财经 · 04-29
阿斯利康(AZN.US)哮喘三联疗法获批上市
明星抗癌药需求强劲，阿斯利康Q1营收和利润均超预期
智通财经 · 04-29
明星抗癌药需求强劲，阿斯利康Q1营收和利润均超预期
阿斯利康(AZN.US)“双免疫治疗”新适应症在华获批上市
智通财经 · 04-27
阿斯利康(AZN.US)“双免疫治疗”新适应症在华获批上市
从“癌种攻坚”到“生态引领”： 阿斯利康肿瘤防治的中国答卷
21世纪经济报道 · 04-21
从“癌种攻坚”到“生态引领”： 阿斯利康肿瘤防治的中国答卷
大摩：将阿斯利康目标价上调至16500便士
中金财经 · 04-08
大摩：将阿斯利康目标价上调至16500便士
加载更多
公司概况
公司名称：
阿斯利康
所属市场：
NYSE
上市日期：
--
主营业务：
阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。
发行价格：
--
{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":185.715,"timestamp":1779994251238,"preClose":185.65,"halted":0,"volume":1210186,"delay":0,"changeRate":0.00035012119579853337,"floatShares":1544000000,"shares":1551000000,"eps":6.639935,"marketStatus":"交易中","change":0.065,"latestTime":"05-28 14:50:52 EDT","open":183.78,"high":185.845,"low":183.36,"amount":223756529.64538,"amplitude":0.013385,"askPrice":185.74,"askSize":12,"bidPrice":185.67,"bidSize":502,"shortable":3,"etf":0,"ttmEps":6.639935,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1779998400000},"marketStatusCode":2,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NYSE","adjPreClose":185.65,"dividendRate":0.01702,"preHourTrading":{"tag":"盘前","latestPrice":183.84,"preClose":185.65,"latestTime":"09:29 EDT","volume":8169,"amount":1498761.5286,"timestamp":1779974999952,"change":-1.81,"changeRate":-0.00975,"amplitude":0.014436},"postHourTrading":{"tag":"盘后","latestPrice":186.908,"preClose":185.65,"latestTime":"19:59 EDT","volume":679308,"amount":126113728.6505,"timestamp":1779926345114,"change":1.258,"changeRate":0.006776,"amplitude":0.006776},"volumeRatio":0.761745,"impliedVol":0.2689,"impliedVolPercentile":0.4263},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2637334314","title":"阿斯利康将在ASCO 2026公布多项III期数据，涵盖肝癌、乳腺癌、膀胱癌及罕见病疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2637334314","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637334314?lang=zh_cn&edition=full","pubTime":"2026-05-22 23:33","pubTimestamp":1779463980,"startTime":"0","endTime":"0","summary":"阿斯利康于5月22日宣布，将在5月29日至6月2日举行的2026年美国临床肿瘤学会年会上，公布超过85篇摘要，涵盖10款已获批药物和13款潜在新药，其中包括25项口头报告。 在肝癌方面，将公布EMERALD-3 III期试验结果。 在膀胱癌方面，将公布POTOMAC III期试验的5年总生存期分析，该试验评估了Imfinzi联合卡介苗治疗高危非肌层浸润性膀胱癌的疗效。 在罕见病方面，将展示anselamimab的III期临床项目数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-22/doc-inhyuwee5028220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0320765992.SGD","LU2237443978.SGD","LU1829250122.USD","LU2417539215.USD","BK4007","BK4585","LU2237443382.USD","LU2237443622.USD","BK4134","LU2462157665.USD","AZN","BK4588","LU0889565916.HKD","LU2456880835.USD","LU0058720904.USD","III","LU2237443549.SGD","BK4568","LU2237443465.HKD","AZNH","LU0289739699.SGD","IE00B3T34201.USD","LU2236285917.USD","LU0109394709.USD","LU2237443895.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637889316","title":"欧洲药品管理局对阿斯利康乳腺癌新药给予积极指导意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2637889316","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637889316?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:57","pubTimestamp":1779447420,"startTime":"0","endTime":"0","summary":"欧洲药品管理局下属委员会22日发布评估结论，对阿斯利康公司研发的实验性乳腺癌药物camizestrant正式出具积极意见。 该决定与美国监管部门此前的初步立场形成对比。数周前，美国食品药品监督管理局顾问委员会曾投票否决该疗法的相关申请。 加速新药获批是阿斯利康扩大全球市场份额的核心战略。据阿斯利康预测，camizestrant仍有望于今年内获得美国监管机构批准，其年销售额峰值预计将突破50亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-22/doc-inhyumqk5199163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AZNH","LU2237443549.SGD","BK4585","LU2462157665.USD","IE00B3T34201.USD","BK4588","LU0320765992.SGD","BK4568","AZN","LU0058720904.USD","LU0289739699.SGD","LU2237443465.HKD","LU0889565916.HKD","LU1829250122.USD","LU2237443382.USD","BK4007","LU2417539215.USD","LU0109394709.USD","LU2237443978.SGD","LU2237443622.USD","LU2456880835.USD","LU2236285917.USD","LU2237443895.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636700080","title":"广药接手达安基因；阿斯利康高血压创新药获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636700080","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636700080?lang=zh_cn&edition=full","pubTime":"2026-05-19 08:01","pubTimestamp":1779148914,"startTime":"0","endTime":"0","summary":"政策动向2026年医保目录调整新增预申报允许商保创新药申报医保目录国家医保局介绍2026年国家医保药品目录及商业健康保险创新药品目录调整工作安排，包括首次允许纳入2025年商保创新药目录的药品申报国家医保目录，新增“预申报”环节等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605193741160824.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193741160824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK0122","BK0168","LU2236285917.USD","AZNH","06978","LU0889565916.HKD","LU2237443382.USD","159992","BK0042","002030","BK0046","LABU","BK1574","BK4568","BK4585","IE00B3T34201.USD","LU2417539215.USD","BK0188","LU2237443622.USD","LU2456880835.USD","LU2237443549.SGD","LU1829250122.USD","BK0159","BK0239","AZN","LU0058720904.USD","LU0289739699.SGD","BK4588","LU0109394709.USD","LU2462157665.USD","BK1161","LU2237443978.SGD","LU2237443895.HKD","LU2237443465.HKD","BK4007","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636023010","title":"阿斯利康(AZN)旗下创新降压药Baxfendy获批 加码高血压治疗领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2636023010","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636023010?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:21","pubTimestamp":1779092477,"startTime":"0","endTime":"0","summary":"从安全性来看，Baxfendy 总体耐受性良好，临床试验期间未发现任何意外安全问题，用药安全性得到充分验证。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300527","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2237443549.SGD","LU2417539215.USD","IE00B3T34201.USD","BK4007","LU0289739699.SGD","LU2237443978.SGD","BK4588","BK4568","LU0109394709.USD","LU2237443895.HKD","LU0320765992.SGD","LU1829250122.USD","AZNH","LU2462157665.USD","LU0889565916.HKD","AZN","LU2237443465.HKD","LU2456880835.USD","LU2236285917.USD","LU2237443382.USD","LU2237443622.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634101862","title":"流行病诊疗板块多股扬升 雅培(ABT)涨1.60%、强生(JNJ)涨1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634101862","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634101862?lang=zh_cn&edition=full","pubTime":"2026-05-12 22:05","pubTimestamp":1778594751,"startTime":"0","endTime":"0","summary":"金吾财讯 | 汉坦病毒疫情叠加药企药物研发/合作进展向好消息提振，美股流行病诊疗板块多股扬升，截至发稿，葛兰素史克 涨 1.93%，雅培 涨 1.60%，默沙东 涨 1.41%，阿斯利康 涨 1.18%，强生 涨 1.12%。达歌生物周二宣布与默沙东研发(中国)有限公司签署合作协议，共同推进抗肿瘤药物临床合作开发。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300341","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","LU2471134879.HKD","MRK","LU2896262040.SGD","LU1732800096.USD","LU0320765646.SGD","LU2361045086.USD","LU1506573853.SGD","LU1974910355.USD","LU1718418525.SGD","LU1778281490.HKD","LU0795875086.SGD","LU1244550577.SGD","LU2211815571.USD","LU1929549753.HKD","LU2236285917.USD","LU0985320562.USD","LU2360032135.SGD","IE0002141913.USD","LU0053666078.USD","BK4559","LU0787776722.HKD","IE00B7SZLL34.SGD","LU0965509010.AUD","LU2357627491.SGD","IE00BKVL7J92.USD","LU1934455863.HKD","LU0994945656.USD","LU1917777945.USD","LU0820562030.AUD","LU1196500208.SGD","LU2125154778.USD","LU1244550494.USD","LU0689626769.HKD","LU0980610538.SGD","LU1674673691.USD","LU1244550221.USD","LU2237443549.SGD","LU2237957811.SGD","LU2361044865.SGD","LU2417539215.USD","SGXZ41872573.SGD","LU0545562505.USD","LU0868494708.USD","LU0882574055.USD","LU2505996681.GBP","LU2089984988.USD","AZN","IE00BGHQF631.EUR","LU1941712264.USD","LU2750360641.GBP","BK4581","LU0426417589.USD","LU1221951046.USD","BK4566","LU0320765992.SGD","IE00BFTCPJ56.SGD","LU0124676726.USD","LU0345769128.USD","LU0466842654.USD","BK4568","LU1093756168.USD","LU1121112475.USD","LU2237443622.USD","LU2430703095.HKD","LU0130517989.USD","LU1201861249.SGD","LU1228905037.USD","LU2602419157.SGD","LU1571399168.USD","SGXZ57979304.SGD","LU1989772840.SGD","GSK.UK","IE0000B7K699.USD","IE00B2B36J28.USD","LU2347655156.SGD","LU1430594728.SGD","LU2403377893.USD","SG9999001176.USD","LU1066051811.HKD","IE00BZ1G4Q59.USD","SG9999004303.SGD","SG9999002232.USD","LU1585245621.USD","LU0098860793.USD","LU1145028129.USD","LU1061106388.HKD","LU2462157665.USD","IE000SO60NU8.SGD","LU2106854487.HKD","LU0114720955.EUR","LU1228905540.USD","IE00B3PB1722.GBP","LU0795875169.SGD","LU2430703251.USD","LU0106261372.USD","LU0265550359.USD","IE00BDGV0183.EUR","IE00BSNM7G36.USD","LU1934455194.USD","SG9999015358.SGD","LU0122379950.USD","IE00BJJMRZ35.SGD","LU1116320737.USD","IE00BBT3K403.USD","LU0345770308.USD","BK4533","LU0238689110.USD","LU0266013472.USD","LU0320765489.SGD","IE00BLSP4239.USD","LU1066053197.SGD","LU2750360997.AUD","LU0208291251.USD","LU0210528500.USD","LU0058720904.USD","IE00BVYPNV92.GBP","LU0942090050.USD","LU1221951129.SGD","IE00BFXG1179.USD","LU1691799644.USD","LU0265550946.USD","IE00BN8TJ469.HKD","LU1894683264.USD","BK4082","LU2023250504.SGD","SG9999001440.SGD","BK4585","LU1074936037.SGD","LU1629891620.HKD","LU0964807845.USD","LU2129689514.USD","BK4534","LU2491050154.USD","BK4504","IE0002270589.USD","LU0203347892.USD","BK4592","LU0889566641.SGD","LU0792757196.USD","SG9999001176.SGD","LU0289739699.SGD","BK4588","IE00B1BXHZ80.USD","LU0109394709.USD","LU0965508806.USD","LU2430703178.SGD","IE00B42XCP33.USD","LU1043141396.HKD","LU0234572021.USD","LU0345770993.USD","LU1829250122.USD","SG9999014567.USD","LU0859254822.USD","LU2471134523.USD","LU2592432038.USD","LU0689472784.USD","LU0648001328.SGD","SG9999002224.SGD","LU1162221912.USD","SG9999015341.SGD","LU1261432733.SGD","LU2471134952.CNY","LU1551013425.SGD","LU2237443382.USD","LU1941712348.USD","IE0001KFT4U8.USD","LU1721429402.USD","LU2491050071.SGD","JNJ","LU1551013342.USD","LU0640476718.USD","LU2237443895.HKD","LU1043141123.HKD","LU1035773651.USD","GSK","BK4516","LU0130102774.USD","LU2112291526.USD","LU2487616109.SGD","LU2505996509.AUD","IE00BJT1NW94.SGD","LU1983299246.USD","LU0070217475.USD","LU1934455277.USD","LU2361044949.HKD","BK4550","IE00BLSP4452.SGD","IE000MB6IJN5.SGD","LU0426412945.USD","LU1732799900.SGD","LU2213496289.HKD","LU2491049909.HKD","LU2756315318.SGD","LU0820561818.USD","SG9999014575.USD","LU1989771016.USD","LU2324357040.USD","LU1093756325.SGD","ABT","LU1935042991.SGD","IE000BZT7R73.USD","LU1116320901.HKD","LU0432979614.USD","LU1032466523.USD","IE00B19Z3B42.SGD","GSKH","LU1059921491.USD","LU1894683348.USD","LU1989763427.SGD","LU2023250330.USD","IE000M9KFDE8.USD","LU1267930813.SGD","LU0006306889.USD","LU0211331839.USD","LU2237443978.SGD","SG9999013999.USD","SG9999014559.SGD","LU1989763690.USD","IE00B4R5TH58.HKD","LU1032955483.USD","LU1057294990.SGD","AZNH","LU0861579265.USD","LU1066051498.USD","LU1069347547.HKD","LU2237443465.HKD","LU1023059063.AUD","LU2461242641.AUD","SGXZ23171101.USD","BK4007","BK4532","LU0070302665.USD","LU2129689431.USD","LU0345769631.USD","LU0889565916.HKD","LU1037948541.HKD","LU0203345920.USD","LU0683600562.USD","LU1496350502.SGD","LU1721429741.USD","LU2023250843.SGD","SG9999014542.SGD","LU1989772923.USD","IE00BVYPNW00.USD","LU0965509101.SGD","LU0943347566.SGD","LU1291159041.SGD","LU2456880835.USD","IE0009355771.USD","LU2129689605.HKD","LU1914381329.SGD","IE00B19Z3581.USD","LU0170899867.USD","LU0210536198.USD","LU0477156953.USD","LU0912757837.SGD","LU0234570918.USD","LU2468319806.SGD","LU1280957306.USD","IE000F7OJYX1.SGD","LU2125154935.USD","LU2133065610.SGD","IE000WAW04H5.SGD","LU2756315664.SGD","LU0868494617.USD","LU0965509283.SGD","LU0820561909.HKD","LU1699723380.USD","LU1066051225.USD","LU2237957902.USD","LU1037948897.HKD","IE0034235303.USD","LU2471134796.USD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2634544008","title":"世界狼疮日｜“主场时刻”患者关爱行动在沪启幕，助百万\"蝶友\"迈向临床缓解新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2634544008","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634544008?lang=zh_cn&edition=full","pubTime":"2026-05-10 20:09","pubTimestamp":1778414940,"startTime":"0","endTime":"0","summary":"在2026年5月10日世界狼疮日，由新华网和患者组织SLE解忧杂货铺联合主办、阿斯利康中国支持的“主场时刻”系统性红斑狼疮患者关爱行动在上海正式启幕。全球范围内系统性红斑狼疮患者人数超过340万。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4955695_ZH55695_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2236285917.USD","BK4568","BK4588","LU1829250122.USD","LU0289739699.SGD","AZN","LU2237443978.SGD","LU2237443622.USD","AZNH","LU2456880835.USD","LU2237443465.HKD","LU0889565916.HKD","LU2237443382.USD","SLE","LU0320765992.SGD","LU2462157665.USD","BK4110","BK4585","LU2237443549.SGD","LU0109394709.USD","ACR","BK4077","LU2237443895.HKD","LU0058720904.USD","LU2417539215.USD","BK4007","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633794147","title":"多家药企高管生变：恒瑞、复星、阿斯利康、辉瑞…","url":"https://stock-news.laohu8.com/highlight/detail?id=2633794147","media":"赛柏蓝","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633794147?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:53","pubTimestamp":1778154780,"startTime":"0","endTime":"0","summary":"01本土制药企业与Biotech迎高管变动恒瑞医药、再鼎医药、百济神州、和铂医药、复星医药映射出了中国创新药发展过程中企业所处的不同阶段。4月16日，恒瑞医药发布公告，正式完成新一届董事会和管理层聘任。复星医药4月2日，复星医药发布首席财务官变更公告，因工作安排调整，陈战宇辞去首席财务官职务。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-05-07/doc-inhxatff4708181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0321505439.SGD","BK4533","02196","LU0868494617.USD","AZN","BK4568","SGXZ57979304.SGD","BK4588","IE00BBT3K403.USD","LU2456880835.USD","LU1023059063.AUD","LU0058720904.USD","AZNH","BK4550","BK4592","01276","600276","LU2237443549.SGD","LU2417539215.USD","LU0306806265.USD","LU2236285917.USD","IE00BLSP4452.SGD","LU0225284248.USD","LU0321505868.SGD","SG9999002232.USD","IE00B19Z3B42.SGD","LU2237443978.SGD","BK4007","LU2237443382.USD","IE00BLSP4239.USD","LU2237443465.HKD","BK4585","06160","LU1894683348.USD","LU2237443622.USD","SG9999003800.SGD","IE00B19Z3581.USD","600196","LU0109394709.USD","LU2462157665.USD","LU2237443895.HKD","LU0225771236.USD","LU0234572021.USD","LU0306807586.USD","LU0456855351.SGD","LU0985481810.HKD","PFE","SG9999001176.SGD","02142","SG9999002224.SGD","LU1829250122.USD","IE0002270589.USD","LU1057294990.SGD","BK4581","SG9999011175.SGD","ONC","LU0170899867.USD","LU1883839398.USD","688235","BK4599","IE000M9KFDE8.USD","LU0889565916.HKD","LU1066053197.SGD","SG9999013999.USD","IE00B3T34201.USD","LU0289739699.SGD","LU1894683264.USD","SG9999001176.USD","LU0122379950.USD","LU0320765992.SGD","LU1066051498.USD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633119830","title":"跨国药企业绩大爆发，集体加仓中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2633119830","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633119830?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:19","pubTimestamp":1778141940,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 2026年第一季度，全球制药巨头的业绩版图再度刷新。 有券商医药行业分析师对21世纪经济报道记者表示，当前跨国药企的业绩已高度“超级重磅药化”，手握“王牌”产品足以决定公司的增长、估值乃至战略走向。默沙东与其他跨国药企一道，已将“加注中国创新”视为战略性防御与进攻并存的长期解法。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BMY","LU0208291251.USD","IE00B2B36J28.USD","LU1066051498.USD","LU0265550946.USD","LU0203347892.USD","BK4516","SG9999001176.USD","IE00B4R5TH58.HKD","LU0106261372.USD","LU1699723380.USD","LU1934455277.USD","LU1934455194.USD","LU2023250843.SGD","BK4599","LU0648001328.SGD","LU2491050154.USD","SG9999014559.SGD","BK4550","LU1035773651.USD","BK4559","LU0859254822.USD","SG9999002232.USD","IE00BZ1G4Q59.USD","LU2360032135.SGD","LU2324357040.USD","LU0868494617.USD","NVS","LU1571399168.USD","NVOH","LU0289739699.SGD","LU1037948541.HKD","LU1941712264.USD","LU1989772840.SGD","IE00BFTCPJ56.SGD","LU1983299246.USD","IE000M9KFDE8.USD","LU0203345920.USD","LU2491049909.HKD","LU1116320737.USD","LU1974910355.USD","SG9999002224.SGD","SGXZ57979304.SGD","FXE","LU0861579265.USD","IE00BLSP4239.USD","LU0980610538.SGD","LU1066051811.HKD","LU1430594728.SGD","LU1989771016.USD","LU1057294990.SGD","LU2361044949.HKD","LU2357627491.SGD","LU0098860793.USD","LU0965509101.SGD","IE00BKVL7J92.USD","BK4533","LU1061106388.HKD","LU2089984988.USD","LU0965509010.AUD","LU0942090050.USD","IE00BLSP4452.SGD","LU0211331839.USD","NVO","IE0002141913.USD","LU2125154778.USD","BK4585","IE00B1BXHZ80.USD","SG9999001440.SGD","SG9999013999.USD","SG9999015358.SGD","LU0130102774.USD","SG9999014567.USD","IE00BJT1NW94.SGD","LU1066051225.USD","MRK","SG9999014542.SGD","LU1066053197.SGD","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU0058720904.USD","LU1162221912.USD","LU0006306889.USD","LU1201861249.SGD","SG9999015341.SGD","LU0122379950.USD","LU0238689110.USD","LU2106854487.HKD","LU1116320901.HKD","LU2468319806.SGD","LU0234572021.USD","LU0130517989.USD","EURmain","LU0985320562.USD","LU0477156953.USD","LU0070302665.USD","LU2125154935.USD","LU2112291526.USD","LU2361044865.SGD","SG9999014575.USD","IE00BSNM7G36.USD","LU1037948897.HKD","LU1929549753.HKD","LU0432979614.USD","LU2461242641.AUD","LU0266013472.USD","LU1941712348.USD","LU1069347547.HKD","LU1917777945.USD","LU1023059063.AUD","LU1934455863.HKD","BK4588","LU0868494708.USD","IE0009355771.USD","EUO","LLY","LU0265550359.USD","LU2023250504.SGD","IE00BBT3K403.USD","LU2491050071.SGD","BK4007","MEURmain","SG9999001176.SGD","AZN","SNY","NVOX","LU1585245621.USD","BK4532","LU2361045086.USD","LU1291159041.SGD","LU1093756168.USD","LU0965509283.SGD","LU0154236417.USD","BK4534","IE00BN8TJ469.HKD","LU0320765489.SGD","LU0965508806.USD","LU0320765646.SGD","LU1989772923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632260556","title":"诚益生物冲刺港股：年亏损4460万美元 业务深度绑定阿斯利康","url":"https://stock-news.laohu8.com/highlight/detail?id=2632260556","media":"雷递网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632260556?lang=zh_cn&edition=full","pubTime":"2026-05-03 10:35","pubTimestamp":1777775725,"startTime":"0","endTime":"0","summary":"诚益生物开曼有限公司（简称：“诚益生物”）日前更新招股书，准备在港交所上市。","market":"sh","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260503/6391340131178578595887971.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260503/6391340131178578595887971.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33522/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["AZN","BK4568","BK4588","LU2456880835.USD","LU0058720904.USD","LU2237443549.SGD","LU2417539215.USD","LU2237443978.SGD","BK4007","LU2237443382.USD","LU2237443465.HKD","BK4585","LU2237443622.USD","LU0109394709.USD","LU2462157665.USD","LU2237443895.HKD","VXUS","LU1829250122.USD","LU0889565916.HKD","IE00B3T34201.USD","LU0289739699.SGD","LU0320765992.SGD","LU2236285917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632619163","title":"伯恩斯坦将阿斯利康目标价从20500便士下调至18600便士。","url":"https://stock-news.laohu8.com/highlight/detail?id=2632619163","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632619163?lang=zh_cn&edition=full","pubTime":"2026-05-01 19:09","pubTimestamp":1777633776,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AZN","AZNH","AZN.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632504618","title":"阿斯利康乳腺癌候选药物未获FDA咨询委员会投票通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2632504618","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632504618?lang=zh_cn&edition=full","pubTime":"2026-05-01 16:14","pubTimestamp":1777623240,"startTime":"0","endTime":"0","summary":"在乳腺癌候选药物未能在一项关键的咨询委员会投票中获得支持后，英国制药集团阿斯利康表示，该公司将继续与美国监管机构合作，对该药物进行审查。该公司周四晚间表示，美国食品药品管理局的肿瘤药物咨询委员会以6比3的投票结果，对乳腺癌治疗候选药物camizestrant的获益-风险评估给出否定性意见。阿斯利康的股价在周五开盘交易中下跌了约1.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-01/doc-inhwktza5459710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","LU0289739699.SGD","LU0058720904.USD","LU2237443465.HKD","LU2237443549.SGD","AZN","LU0109394709.USD","LU1829250122.USD","LU2462157665.USD","LU2456880835.USD","IE00B3T34201.USD","LU0889565916.HKD","AZN.UK","BK4007","AZNH","LU0320765992.SGD","BK4568","BK4588","LU2237443382.USD","LU2237443978.SGD","LU2237443895.HKD","LU2237443622.USD","LU2417539215.USD","LU2236285917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161357099","title":"FDA顾问委员会推荐阿斯利康Truqap用于PTEN缺陷型转移性激素敏感性前列腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1161357099","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161357099?lang=zh_cn&edition=full","pubTime":"2026-05-01 05:49","pubTimestamp":1777585759,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局顾问委员会近日对阿斯利康制药旗下抗癌药物Truqap给予积极推荐，支持其用于治疗PTEN缺陷型转移性激素敏感性前列腺癌患者。该研究证实，在PTEN缺失的转移性激素敏感性前列腺癌患者中，Truqap治疗方案能显著延长影像学无进展生存期，为这类特定人群提供了新的精准治疗选择。FDA通常遵循顾问委员会的建议，但最终决定仍待官方审评。若获批，Truqap将成为首个针对PTEN缺陷型mHSPC的靶向疗法，填补当前治疗格局中的重要空白。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","LU0827474353.SGD","LU0052756011.USD","AZN.UK","LU0957799991.USD","LU0047473722.SGD","IE0002141913.USD","LU0757432116.USD","LU0964806797.USD","LU2125909593.SGD","LU0738911758.USD","BK5011","LU0887340254.USD","LU2357627491.SGD","LU0211326755.USD","LU0390134368.USD","LU0708994859.HKD","IE0034235188.USD","LU0545039389.USD","LU0882574055.USD","LU2089984988.USD","AZN","LU0920840948.USD","IE00BFTCPJ56.SGD","SG9999013999.USD","LU1078025761.USD","SGXZ57979304.SGD","LU0047473722.EUR","LU2125909247.SGD","LU1989772840.SGD","LU1003077747.HKD","IE00B2B36J28.USD","LU2108987350.USD","SG9999001176.USD","LU1019634622.SGD","LU1487256676.USD","LU1061106388.HKD","LU1273509221.SGD","LU1170363599.USD","LU0114720955.EUR","LU1814569148.SGD","LU0661504455.SGD","LU2091194634.USD","LU2293690082.USD","LU0499090636.EUR","LU2539964713.USD","LU0122379950.USD","IE00BJJMRZ35.SGD","LU0266013472.USD","IE00BKPKM643.USD","LU0058720904.USD","LU0553294199.USD","LU0823416689.USD","LU2089284900.SGD","LU1880407215.USD","LU0972486137.USD","LU0011850046.USD","LU1267930490.SGD","LU0784385840.USD","LU1481600234.SGD","LU0203347892.USD","LU0889566641.SGD","LU0792757196.USD","SG9999001176.SGD","LU0526926950.USD","LU1119994496.HKD","LU0289739699.SGD","LU1084165304.USD","LU1015430645.USD","LU0949170426.SGD","LU0345777659.USD","LU0859254822.USD","LU0976567544.SGD","LU0960981461.USD","LU1046234339.USD","LU1481599808.USD","LU0171293334.USD","LU1261432733.SGD","LU0128525929.USD","LU0128525689.USD","LU1003076772.USD","LU0784383803.USD","LU1064927863.SGD","LU2112291526.USD","LU1104425308.USD","LU2114397693.USD","LU0158827948.USD","LU0496365809.HKD","LU0889565080.SGD","IE00BJT1NW94.SGD","LU1983299246.USD","LU0310800965.SGD","LU2433249047.HKD","LU1196032939.SGD","LU0211327993.USD","LU0310800379.SGD","LU0211328371.USD","LU0640478417.SGD","LU0997586515.USD","LU0969580561.USD","LU1051770623.HKD","LU1989771016.USD","LU1267930573.SGD","LU2324357040.USD","LU0432979614.USD","LU2293690249.USD","LU0029864427.USD","LU1267930813.SGD","LU0310799852.SGD","IE00B4R5TH58.HKD","LU1057294990.SGD","AZNH","LU0949170772.SGD","LU1023059063.AUD","LU0211326839.USD","LU0823399737.USD","LU0997586432.USD","LU0203345920.USD","LU1496350502.SGD","LU1989772923.USD","LU1291159041.SGD","LU0575583348.USD","IE0009355771.USD","LU1153584641.USD","LU2355687059.USD","LU2089283258.USD","LU1323610961.USD","LU0345777147.USD","LU0920783379.SGD","LU1496350171.SGD","LU0784385170.HKD","LU2468319806.SGD","LU1301847155.USD","LU0557290698.USD","LU0784384876.USD","LU2133065610.SGD","LU0077335932.USD","LU1153585028.USD","LU2023251221.USD","LU0857590862.USD","LU1923622614.USD","LU1267930227.SGD","LU1880407132.USD","LU1019632923.USD","LU0963555726.SGD","LU2279689827.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171095508","title":"阿斯利康行使选择权 根据协议条款向Pintree Therapeutics支付2500万美元交割款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1171095508","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171095508?lang=zh_cn&edition=full","pubTime":"2026-04-30 07:03","pubTimestamp":1777503805,"startTime":"0","endTime":"0","summary":"根据双方达成的协议条款，阿斯利康制药行使选择权，此举触发了其向Pintree Therapeutics支付一笔高达2500万美元的选择权交割款项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2433249047.HKD","LU0047473722.SGD","LU1880407215.USD","LU2112291526.USD","LU0211326839.USD","LU1487256676.USD","LU1104425308.USD","LU0784385170.HKD","LU1267930490.SGD","LU0976567544.SGD","LU2108987350.USD","LU0889566641.SGD","LU1170363599.USD","LU2114397693.USD","LU1019634622.SGD","LU0553294199.USD","LU1273509221.SGD","LU1496350502.SGD","LU1196032939.SGD","LU0859254822.USD","LU0969580561.USD","LU1153584641.USD","LU1301847155.USD","IE00BJJMRZ35.SGD","LU0784384876.USD","LU0920783379.SGD","LU1019632923.USD","LU0390134368.USD","LU2468319806.SGD","LU1814569148.SGD","LU1119994496.HKD","IE0009355771.USD","LU0997586432.USD","LU0792757196.USD","IE00B3T34201.USD","LU2089284900.SGD","IE00BKPKM643.USD","LU0158827948.USD","LU2125909247.SGD","LU0757432116.USD","LU2293690082.USD","LU0949170772.SGD","LU0964806797.USD","LU1481599808.USD","LU1989772840.SGD","LU1267930227.SGD","LU0827474353.SGD","LU0345777659.USD","SG9999001176.SGD","LU0211326755.USD","SG9999001176.USD","LU0889565080.SGD","LU1064927863.SGD","IE00BJT1NW94.SGD","LU0203347892.USD","LU0963555726.SGD","LU0310800965.SGD","IE0002141913.USD","LU2125909593.SGD","LU1267930813.SGD","LU0052756011.USD","LU0211328371.USD","AZN","LU2133065610.SGD","LU2357627491.SGD","SGXZ57979304.SGD","LU0289739699.SGD","LU1291159041.SGD","LU1880407132.USD","LU2023251221.USD","LU0128525689.USD","LU0058720904.USD","LU0823399737.USD","LU0960981461.USD","LU0575583348.USD","LU0784383803.USD","LU1153585028.USD","LU1051770623.HKD","LU0545039389.USD","LU1003077747.HKD","LU1983299246.USD","LU0997586515.USD","LU0972486137.USD","LU0526926950.USD","AZNH","LU0114720955.EUR","LU0882574055.USD","LU2539964713.USD","LU0640478417.SGD","LU0957799991.USD","LU1496350171.SGD","LU0171293334.USD","LU0128525929.USD","LU1261432733.SGD","LU0011850046.USD","LU0738911758.USD","LU0310799852.SGD","LU1989771016.USD","LU0949170426.SGD","LU0345777147.USD","SG9999013999.USD","LU1023059063.AUD","LU0029864427.USD","LU1061106388.HKD","LU0122379950.USD","LU0310800379.SGD","LU0203345920.USD","LU2324357040.USD","AZN.UK","LU2089984988.USD","LU0496365809.HKD","LU0661504455.SGD","LU2279689827.SGD","LU0784385840.USD","LU0557290698.USD","LU0211327993.USD","LU0887340254.USD","LU1057294990.SGD","LU0857590862.USD","LU1078025761.USD","LU0077335932.USD","LU1989772923.USD","LU2293690249.USD","LU0047473722.EUR","LU0499090636.EUR","IE00BFTCPJ56.SGD","LU2091194634.USD","LU0432979614.USD","LU1084165304.USD","LU1323610961.USD","LU0708994859.HKD","LU1046234339.USD","LU1003076772.USD","LU1015430645.USD","LU2355687059.USD","LU0823416689.USD","LU2089283258.USD","BK5011","IE00B4R5TH58.HKD","LU1923622614.USD","IE0034235188.USD","LU1481600234.SGD","IE00B2B36J28.USD","LU0266013472.USD","LU1267930573.SGD","LU0920840948.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159873248","title":"阿斯利康宣布3亿英镑对英投资，涵盖去年暂停的剑桥研发基地后续建设","url":"https://stock-news.laohu8.com/highlight/detail?id=1159873248","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159873248?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:51","pubTimestamp":1777463500,"startTime":"0","endTime":"0","summary":"阿斯利康制药首席执行官帕斯卡尔·索里奥特今日宣布，公司将对英国投资3亿英镑。此项投资计划包含完成去年一度暂停的剑桥研发基地建设项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0949170772.SGD","LU1119994496.HKD","LU0289739699.SGD","SG9999001176.USD","LU0575583348.USD","IE0034235188.USD","LU0557290698.USD","LU0128525929.USD","LU0052756011.USD","LU2293690082.USD","LU0957799991.USD","LU2112291526.USD","LU0310800965.SGD","LU0496365809.HKD","LU2357627491.SGD","LU0963555726.SGD","SGXZ57979304.SGD","LU1487256676.USD","LU2539964713.USD","LU0545039389.USD","LU1291159041.SGD","LU0757432116.USD","LU1023059063.AUD","LU0823399737.USD","LU0211327993.USD","LU0211326755.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0158827948.USD","LU0211326839.USD","LU0784383803.USD","LU1273509221.SGD","LU0997586515.USD","LU2089283258.USD","LU0047473722.SGD","IE00B3T34201.USD","LU0345777147.USD","AZN","LU0203345920.USD","LU0114720955.EUR","LU0859254822.USD","LU0077335932.USD","LU0823416689.USD","LU1003077747.HKD","IE0009355771.USD","LU1064927863.SGD","LU1153584641.USD","LU0122379950.USD","LU0784385840.USD","IE00B2B36J28.USD","LU0310800379.SGD","LU0011850046.USD","LU0972486137.USD","LU0857590862.USD","LU1267930490.SGD","LU0029864427.USD","IE00B4R5TH58.HKD","LU0949170426.SGD","LU0997586432.USD","LU1015430645.USD","LU1323610961.USD","IE00BJT1NW94.SGD","LU2125909247.SGD","LU0058720904.USD","LU0889565080.SGD","LU1983299246.USD","LU1019632923.USD","LU1153585028.USD","LU0211328371.USD","LU2091194634.USD","LU1170363599.USD","LU0784385170.HKD","LU1104425308.USD","LU1989771016.USD","AZNH","LU1051770623.HKD","LU1019634622.SGD","IE00BFTCPJ56.SGD","LU1196032939.SGD","LU1267930227.SGD","LU1496350502.SGD","LU1084165304.USD","LU0266013472.USD","LU1496350171.SGD","LU0964806797.USD","BK5011","LU1046234339.USD","LU0553294199.USD","LU2108987350.USD","AZN.UK","LU1267930813.SGD","LU0640478417.SGD","LU2324357040.USD","LU1923622614.USD","LU1267930573.SGD","LU0661504455.SGD","LU0887340254.USD","LU1261432733.SGD","SG9999013999.USD","LU1003076772.USD","LU0499090636.EUR","LU1814569148.SGD","LU1880407132.USD","LU0920840948.USD","LU1057294990.SGD","LU0432979614.USD","LU1061106388.HKD","LU0203347892.USD","LU0708994859.HKD","IE00BKPKM643.USD","LU1301847155.USD","LU0345777659.USD","LU0784384876.USD","LU0792757196.USD","LU2293690249.USD","LU0889566641.SGD","LU2114397693.USD","LU0310799852.SGD","LU0047473722.EUR","LU1078025761.USD","LU0128525689.USD","LU2133065610.SGD","LU0976567544.SGD","LU1880407215.USD","LU2433249047.HKD","SG9999001176.SGD","LU1481599808.USD","LU0738911758.USD","LU0827474353.SGD","LU0960981461.USD","LU0390134368.USD","LU0969580561.USD","LU2125909593.SGD","LU2355687059.USD","LU2023251221.USD","LU1989772840.SGD","LU1989772923.USD","LU2279689827.SGD","LU0920783379.SGD","LU0882574055.USD","LU1481600234.SGD","LU0171293334.USD","LU2089284900.SGD","LU2089984988.USD","LU0526926950.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125435733","title":"阿斯利康CEO：英美医药协议将惠及患者，提升药物可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1125435733","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125435733?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:35","pubTimestamp":1777462524,"startTime":"0","endTime":"0","summary":"阿斯利康制药首席执行官帕斯卡尔·索里奥表示，近期达成的美国与英国之间的医药合作协议，将有效改善患者的药物获取渠道。索里奥在媒体电话会议上指出，这一合作框架有望简化新药审批流程，并促进创新疗法更快速地惠及有需要的患者群体。他强调，加强国际协作对于应对全球健康挑战至关重要，而此项协议正是推动医药领域进步的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1084165304.USD","LU0960981461.USD","LU1104425308.USD","LU1880407215.USD","LU1003077747.HKD","LU1481600234.SGD","LU1064927863.SGD","LU0784384876.USD","LU1323610961.USD","LU0310800379.SGD","LU0963555726.SGD","LU1196032939.SGD","SGXZ57979304.SGD","LU1153584641.USD","LU0972486137.USD","LU2108987350.USD","LU0708994859.HKD","LU2112291526.USD","LU0949170772.SGD","LU2091194634.USD","LU0792757196.USD","LU0128525689.USD","LU1261432733.SGD","LU1019632923.USD","LU1496350502.SGD","LU0997586432.USD","LU1153585028.USD","LU2279689827.SGD","LU0784385170.HKD","LU2089984988.USD","IE0002141913.USD","LU0122379950.USD","LU0920783379.SGD","LU1015430645.USD","IE0034235188.USD","IE00B3T34201.USD","SG9999001176.SGD","LU0889565080.SGD","LU2125909593.SGD","LU0889566641.SGD","LU2293690082.USD","LU0949170426.SGD","IE00B2B36J28.USD","LU0757432116.USD","LU0969580561.USD","LU1019634622.SGD","LU2089284900.SGD","LU0390134368.USD","LU1061106388.HKD","LU0211326755.USD","LU1057294990.SGD","LU2468319806.SGD","LU1989772840.SGD","LU1291159041.SGD","LU1023059063.AUD","LU0310799852.SGD","IE00BFTCPJ56.SGD","LU2433249047.HKD","LU1487256676.USD","LU0859254822.USD","LU0203345920.USD","LU0158827948.USD","LU0827474353.SGD","LU0545039389.USD","LU1814569148.SGD","LU0882574055.USD","IE00BJJMRZ35.SGD","LU0211326839.USD","LU0345777659.USD","BK5011","LU0432979614.USD","LU2357627491.SGD","LU1496350171.SGD","LU0171293334.USD","LU1003076772.USD","LU0823399737.USD","LU0964806797.USD","LU2293690249.USD","LU1267930227.SGD","IE00BJT1NW94.SGD","LU0077335932.USD","LU0784385840.USD","LU1989772923.USD","LU1880407132.USD","LU1983299246.USD","IE00BKPKM643.USD","LU0997586515.USD","LU0661504455.SGD","SG9999001176.USD","LU0784383803.USD","LU0203347892.USD","LU0575583348.USD","LU0887340254.USD","LU2133065610.SGD","LU0345777147.USD","LU1273509221.SGD","LU1119994496.HKD","LU1923622614.USD","LU0310800965.SGD","LU2355687059.USD","LU1481599808.USD","LU1170363599.USD","SG9999013999.USD","LU0496365809.HKD","LU0011850046.USD","LU0052756011.USD","LU2023251221.USD","LU1301847155.USD","LU0211328371.USD","LU1267930813.SGD","LU2125909247.SGD","AZN","LU0738911758.USD","LU0857590862.USD","LU1267930573.SGD","LU0047473722.EUR","LU0499090636.EUR","LU0289739699.SGD","AZNH","LU0920840948.USD","LU1989771016.USD","LU1267930490.SGD","LU0047473722.SGD","LU0266013472.USD","LU0526926950.USD","LU1046234339.USD","LU2089283258.USD","LU0128525929.USD","LU0114720955.EUR","LU1051770623.HKD","LU2539964713.USD","LU0058720904.USD","IE00B4R5TH58.HKD","LU0823416689.USD","LU0553294199.USD","LU1078025761.USD","LU0029864427.USD","LU0957799991.USD","LU0640478417.SGD","AZN.UK","LU0211327993.USD","LU0557290698.USD","LU0976567544.SGD","IE0009355771.USD","LU2324357040.USD","LU2114397693.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631567485","title":"阿斯利康(AZN.US)哮喘三联疗法获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2631567485","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631567485?lang=zh_cn&edition=full","pubTime":"2026-04-29 16:28","pubTimestamp":1777451308,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月28日，阿斯利康宣布布地格福吸入气雾剂获得FDA批准用于维持治疗12岁及以上哮喘患者。布地格福是阿斯利康开发的一款固定剂量三联疗法，包含布地奈德、格隆溴铵、福莫特罗三种药物活性成分。FDA此次批准是基于两项III期研究的积极结果。结果显示，相较于Symbicort组，布地格福吸入气雾剂组患者的1秒内用力呼气量显著改善，并且重度哮喘恶化发生率显著降低。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU2236285917.USD","LU2417539215.USD","AZN","LU0109394709.USD","LU0889565916.HKD","LU2237443622.USD","LU2237443895.HKD","LU0320765992.SGD","LU2462157665.USD","LU0289739699.SGD","LU2237443549.SGD","BK4568","LU1829250122.USD","LU0058720904.USD","LU2237443465.HKD","BK4007","LU2237443978.SGD","IE00B3T34201.USD","LU2237443382.USD","BK4588","IPOS","LU2456880835.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631561829","title":"明星抗癌药需求强劲，阿斯利康Q1营收和利润均超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2631561829","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631561829?lang=zh_cn&edition=full","pubTime":"2026-04-29 15:10","pubTimestamp":1777446600,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，受明星抗癌药物需求的推动，阿斯利康第一季度利润增长超预期。财报显示，阿斯利康第一季度总营收152.88亿美元，同比增长8%，超出市场预期；调整后每股收益为 2.58 美元，高于分析师预期的 2.55 美元。继 2025 年股价大幅上涨 32% 后，阿斯利康的股价今年至今基本持平。虽然抗癌药物一直是阿斯利康成功的关键，但其针对心血管和代谢疾病的产品组合销售额在第一季度有所下降。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436063.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"明星抗癌药需求强劲，阿斯利康Q1营收和利润均超预期","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630369561","title":"阿斯利康(AZN.US)“双免疫治疗”新适应症在华获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2630369561","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630369561?lang=zh_cn&edition=full","pubTime":"2026-04-27 16:54","pubTimestamp":1777280053,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月27日，阿斯利康宣布，中国国家药品监督管理局已正式批准英飞凡联合英卓凡用于晚期或不可切除的肝细胞癌成人患者的一线治疗。本次新适应症的批准是基于全球 III 期 HIMALAYA 研究及中国队列的积极结果。数据显示，STRIDE 方案组与度伐利尤单抗单药组的三级及以上治疗相关不良事件发生率分别为 24.1% 和 12.4%，均低于索拉非尼组的 40.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1829250122.USD","LU2237443622.USD","LU0109394709.USD","BK4007","BK4568","LU2456880835.USD","LU2237443382.USD","AZN","BK4588","IE00B3T34201.USD","LU2236285917.USD","LU2237443465.HKD","IPOS","LU0058720904.USD","LU0889565916.HKD","LU2417539215.USD","LU0289739699.SGD","LU2462157665.USD","LU0320765992.SGD","LU2237443895.HKD","LU2237443549.SGD","BK4585","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629892730","title":"从“癌种攻坚”到“生态引领”： 阿斯利康肿瘤防治的中国答卷","url":"https://stock-news.laohu8.com/highlight/detail?id=2629892730","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629892730?lang=zh_cn&edition=full","pubTime":"2026-04-21 16:33","pubTimestamp":1776760380,"startTime":"0","endTime":"0","summary":"癌症长期位居全球第二大致死原因，而中国以全球最高的新发和死亡人数，站在抗癌最前线。行业正直面一个关键问题：如何通过真正的科学突破，持续降低死亡负担，改善患者生存期与生活质量。这从来不是一句空泛的口号，而是一场必须打赢的硬仗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604213712331011.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604213712331011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2237443622.USD","LU2237443978.SGD","BK4588","LU0289739699.SGD","BK4585","LU0109394709.USD","LU2237443895.HKD","LU2462157665.USD","LU2236285917.USD","LU2456880835.USD","LU2237443382.USD","LU2237443465.HKD","IE00B3T34201.USD","BK4007","LU2237443549.SGD","LU0320765992.SGD","LU1829250122.USD","LU2417539215.USD","AZN","BK4568","LU0889565916.HKD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625990082","title":"大摩：将阿斯利康目标价上调至16500便士","url":"https://stock-news.laohu8.com/highlight/detail?id=2625990082","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625990082?lang=zh_cn&edition=full","pubTime":"2026-04-08 14:27","pubTimestamp":1775629621,"startTime":"0","endTime":"0","summary":"摩根士丹利将阿斯利康目标股价从16000便士上调至16500便士。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260408/32130641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0097},{"period":"1month","weight":-0.0099},{"period":"3month","weight":-0.0899},{"period":"6month","weight":0.0011},{"period":"1year","weight":0.3081},{"period":"ytd","weight":0.0097}],"compareEarnings":[{"period":"1week","weight":0.0124},{"period":"1month","weight":0.0493},{"period":"3month","weight":0.0887},{"period":"6month","weight":0.0981},{"period":"1year","weight":0.2695},{"period":"ytd","weight":0.1005}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.001662},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.012868},{"month":3,"riseRate":0.545455,"avgChangeRate":0.025511},{"month":4,"riseRate":0.636364,"avgChangeRate":0.028791},{"month":5,"riseRate":0.515152,"avgChangeRate":0.008208},{"month":6,"riseRate":0.454545,"avgChangeRate":0.018334},{"month":7,"riseRate":0.606061,"avgChangeRate":-0.002513},{"month":8,"riseRate":0.484848,"avgChangeRate":0.004788},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007464}],"exchange":"NYSE","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}